The story of Viagra, formerly marketed by copyright, presents a complex case study for backers considering the pharmaceutical landscape . While its initial success and impact of vast in sales, the intellectual property end has opened the way for alternative medications, substantially diminishing earnings prospects . This shift raises doubts about t